Partner With Us NRI

Glenmark Pharmaceuticals Ltd share Price

Company details

6M Return 47.49%
1Y Return 60.86%
Mkt Cap.(Cr) 17,947.30
Volume 1,140,652
Div Yield 0.39%
OI Chg %
Volume 1,140,652

Open Free Trading Account Online with ICICIDIRECT

Margin recovery hinges on key launches, cost control…

About The Stock

    Glenmark’s business is separated into three entities –

    • Glenmark Pharmaceuticals for building a global generic, specialty and OTC business in therapy areas of dermatology, respiratory, oncology among others
    • Glenmark Life Sciences for manufacturing and marketing APIs
    • Innovation new company (ICHNOS) to focus on discovery and development of novel, first‐in‐class treatments in the therapeutic areas of immunology, oncology and pain encompassing both NBEs as well as NCEs


    Glenmark reported some traction in India (ex-Covid), Europe and RoW but US performance was subdued (both YoY and QoQ and so were margins

    • Sales were up 6% YoY to ₹ 3019 crore
    • EBITDA was at ₹ 463 crore, down 11% YoY with margins at 15.3%
    • Adjusted PAT was at ₹ 238 crore (up 2% YoY) [Note: Profit adjusted for one-time loss of ₹ 82.5 crore due to recall and Monroe facility remediation]

Click here for full recommendation

Research view on more stocks

Glenmark Pharmaceuticals Ltd.

Q4FY23 Quarterly & FY23 Annual Result Announced for Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals announced Q4FY23 & FY23 results:

  • Q4FY23:
    • ROW Business grew by 25.1% YoY to Rs 6,856 million
    • Europe Business grew by 22.3% YoY to Rs 6,078 million
    • North America Business recorded growth of 15.3% YoY to Rs 8,507 million
    • India Business recorded a decline of 6.4% YoY to Rs 8,284 million
    • EBITDA was at Rs 6,050 million, with a margin of 17.9%
    • Consolidated revenue was at Rs 33,737 million vs Rs 30,191 million recording an increase of 11.7% YoY
    • EBITDA was Rs 6,050 million in Q4FY23, as compared to Rs 4,634 million in Q4FY22, registering growth of 30.5%. EBITDA margin for Q4FY23 was 17.9 %.
    • Reported net loss of Rs 4,031 million for Q4FY23 on account of an exceptional loss of Rs 7,997 million, primarily on account of the settlement of the litigation related to generic Zetia in the U.S.
  • FY23:
    • Consolidated revenue was at Rs 1,29,901 million as against Rs 1,23,049 million, recording an increase of 5.6 % over FY22
    • EBITDA for FY23 stood at Rs 22,784 million as against Rs 23,203 million in FY22
    • EBITDA margin for FY 2022-23 was at 17.5%
    • Net Profit (PAT) was at Rs 3,774 million for FY23, as against Rs 9,936 million in FY22. The PAT for FY23 was lower on account of an exceptional loss of Rs 7,659 million primarily on account of the settlement of the litigation related to generic Zetia in the U.S.

“We delivered yet another year of robust performance, despite the challenging global macro-economic environment. Our India business recorded double-digit growth in secondary sales. The North American business showed a strong recovery, and the EU and RoW markets did phenomenally well. We continued to make headway in launching Ryaltris®, our first globally branded specialty product. Additionally, we initiated the Proof-of-Concept studies for four of our clinical oncology assets, which are part of the Glenmark/Ichnos pipeline,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.

He further added, “We look forward to continue this momentum in the coming year with double-digit revenue growth and significant improvement in EBITDA margins.”



Result PDF

View Other Company Results


Investment recommendation

Margin recovery hinges on key launches, cost control…
Call Date
13 Feb 2023
Entry Price 410.00
Target Price 440.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Glenmark Pharmaceuticals Ltd Stocks COMPARISION


Equity Capital: 9,086.65 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 7,434.08 30,851.81
LAST 3M 18,139.88 59,059.53
LAST 6M 65,342.23 45,150.76
LAST 12M 117,520.45 98,037.67

Glenmark Pharmaceuticals Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Glenmark Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company manufacturing generic drugs and active pharmaceutical ingredients. It was founded in 1977 by Gracias Saldanha. The company’s headquarters are in Mumbai. For FY 2021-2022, Glenmark Pharmaceuticals Ltd.’s total revenue was Rs 12,471.58 crore, up 13.44% from Rs 10,994.15 crore in the previous financial year 2020-2021. On 8 August 2022, the company’s market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/glenmarkpharma/GP08" 10,483 crore. 

    The company is listed on the Bombay Stock Exchange with the code 532296 and on the National Stock Exchange with the code GLENMARK.  

    Glenmark Pharmaceuticals Ltd. is involved in developing and marketing branded and generic formulations. The company’s innovative drug discovery effort focuses on the areas of metabolic disorders (obesity, diabetes, etc.), inflammation (rheumatoid arthritis, asthma/COPD, etc.), and pain (inflammatory pain and neuropathic pain). It manufactures formulations across therapeutic areas of respiratory, diabetes, cardiac, dermatology, gynaecology, anti-infective, oncology, and CNS.  

    The company’s shareholding pattern on 30 June 2022 showed a promoter stake of 46.65%, foreign institutional investor stake of 24.23%, domestic institutional investor stake of 10.49%, and public stake of 18.62%. The Saldanha Family Trust is the leading promoter with a 45.45% share. During the quarter ended June 2022, mutual funds decreased holdings from 6.18% to 5.81%, with the number of mutual fund schemes reducing from 21 to 19.  

    Mr Glenn Saldanha is the company’s chairman and managing director. The top management comprises Mr D R Mehta, Mr Sridhar Gorthi, Mr Dipankar Bhattacharjee, Mr Rajesh V Desai, Mrs Cherylann Pinto, Mrs B E Saldanha, Mr Bernard Munos, Dr Brian W Tempest, Mr V S Mani, and Ms Saira Ramasastry. The auditors are Suresh Surana & Associates LLP and Walker, Chandiok & Co.LLP.  

    On 8 August 2022, Glenmark Pharmaceuticals Ltd.’s BSE share price was trending at Rs 372.45, while the NSE share price was trending at Rs 372.50. The 52-week high for Glenmark Pharmaceuticals Ltd.’s share price was Rs 597.90, and the 52-week low for the company’s share price was Rs 348.50.  

    The company’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd. 

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai, Maharashtra, 400026

Tel : 91-22-40189999
Email : complianceofficer:glenmarkpharma.com
Website : http://www.glenmarkpharma.com

Karvy Computershare Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 532296
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE935A01035

FAQ’s on Glenmark Pharmaceuticals Ltd Shares

You can buy Glenmark Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glenmark Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 09, 2023 03:58 PM the closing price of Glenmark Pharmaceuticals Ltd was ₹ 636.05.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Jun 09, 2023 03:58 PM, the market cap of Glenmark Pharmaceuticals Ltd stood at ₹ 17,947.30.

The latest PE ratio of Glenmark Pharmaceuticals Ltd as of Jun 09, 2023 03:58 PM is 31.87

The latest PB ratio of Glenmark Pharmaceuticals Ltd as of Jun 09, 2023 03:58 PM is 0.53

The 52-week high of Glenmark Pharmaceuticals Ltd is ₹ 682.25 while the 52-week low is ₹ 348.50

According to analyst recommendations, Glenmark Pharmaceuticals Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app